Mondrian Investment Partners LTD Takes Position in Kenvue Inc. $KVUE

Mondrian Investment Partners LTD purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 4,884,095 shares of the company’s stock, valued at approximately $79,269,000. Mondrian Investment Partners LTD owned about 0.25% of Kenvue at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in KVUE. Vanguard Group Inc. boosted its holdings in Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after purchasing an additional 4,101,880 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in shares of Kenvue by 27.1% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 310,686 shares of the company’s stock worth $5,042,000 after buying an additional 66,192 shares during the last quarter. Aviva PLC grew its position in shares of Kenvue by 6.8% in the second quarter. Aviva PLC now owns 1,432,477 shares of the company’s stock valued at $29,982,000 after purchasing an additional 91,744 shares during the last quarter. Bessemer Group Inc. grew its holdings in Kenvue by 40.6% during the 2nd quarter. Bessemer Group Inc. now owns 3,319,933 shares of the company’s stock valued at $69,487,000 after buying an additional 958,757 shares during the last quarter. Finally, Ethic Inc. boosted its stake in shares of Kenvue by 7.8% during the second quarter. Ethic Inc. now owns 237,758 shares of the company’s stock valued at $4,964,000 after acquiring an additional 17,189 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Barclays lifted their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Jefferies Financial Group lowered shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the company from $23.00 to $18.00 in a report on Friday, January 30th. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Evercore set a $18.00 target price on shares of Kenvue in a research report on Tuesday, October 28th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Four analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $19.46.

Kenvue Price Performance

KVUE opened at $18.70 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The company’s 50-day moving average price is $17.42 and its 200 day moving average price is $17.68. The firm has a market cap of $35.82 billion, a price-to-earnings ratio of 24.93 and a beta of 0.59. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be given a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Insiders Place Their Bets

In other news, Director Jeffrey C. Smith bought 3,200,000 shares of Kenvue stock in a transaction on Friday, December 12th. The stock was purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the purchase, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.17% of the stock is currently owned by corporate insiders.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.